¿Se pueden disminuir las dosis de hidroxicloroquina en pacientes con lupus en remisión prolongada?

Autor: Adriana Carlomagno, Gonzalo Silveira, Martín Rebella, José Mario Sabio, Álvaro Danza

Publikováno v: Revista Médica del Uruguay, Vol 34, Iss 1, Pp 63-64 (2019)

Carta al editor

Externí odkaz: https://doaj.org/article/00501d0114764208812e26eafcd3e615

Nefritis lúpica Experiencia con dosis reducidas de glucocorticoides en una unidad de enfermedades autoinmunes sistémicas

Autor: Ana Carina Pizzarossa, Ãlvaro Danza, Gonzalo Silveira, Martín Rebella, Federico Yandian, Adriana Carlomagno, Martín Yandian

Publikováno v: REVISTA MEDICA DEL URUGUAY. 37

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c7638fd5020b0815d8c777d62cd50ae5
https://doi.org/10.29193/rmu.37.4.6

Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues

Autor: Ãlvaro Danza, Adriana Carlomagno, María Cecilia Goizueta, Guillermo Ruiz-Irastorza, Maira Arias Saavedra, Florencia Vivero, Sabrina Porta

Publikováno v: Journal of Clinical Medicine, Vol 9, Iss 2709, p 2709 (2020)

Since the discovery of glucocorticoids (GCs), their important anti-inflammatory effect, rapid mechanism of action, low cost, and accessibility have made them one of the mainstays of treatment for Systemic lupus erythematosus (SLE). Although their use

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::552055546e46b9b11fb7ec9e79a8a03a
https://www.mdpi.com/2077-0383/9/9/2709

A novel form of Deleted in breast cancer 1 (DBC1) lacking the N-terminal domain does not bind SIRT1 and is dynamically regulated in vivo

Autor: Leonardo Santos, Adriana Carlomagno, Paola Contreras, Jose L. Badano, Florencia Irigoín, Inés Marmisolle, Carlos Escande, Mikkel H. Vendelbo, Victoria Prieto-Echagüe, Rosario Durán, José R. Sotelo-Silveira, Celia Quijano, Aldo J Calliari, Alejandro Leyva, Claudia C.S. Chini, Eduardo N. Chini, Laura Colman, Mariana Bresque

Publikováno v: Scientific Reports
Santos, L, Colman, L, Contreras, P, Chini, C C, Carlomagno, A, Leyva, A, Bresque, M, Marmisolle, I, Quijano, C, Durán, R, Irigoín, F, Prieto-Echagüe, V, Vendelbo, M H, Sotelo-Silveira, J R, Chini, E N, Badano, J L, Calliari, A J & Escande, C 2019, ' A novel form of Deleted in breast cancer 1 (DBC1) lacking the N-terminal domain does not bind SIRT1 and is dynamically regulated in vivo ', Scientific Reports, vol. 9, no. 1, 14381 . https://doi.org/10.1038/s41598-019-50789-7
COLIBRI
Universidad de la República
instacron:Universidad de la República
Scientific Reports, Vol 9, Iss 1, Pp 1-14 (2019)

The protein Deleted in Breast Cancer-1 is a regulator of several transcription factors and epigenetic regulators, including HDAC3, Rev-erb-alpha, PARP1 and SIRT1. It is well known that DBC1 regulates its targets, including SIRT1, by protein-protein i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::698a98d435528f34075f82cd7c250ec7
http://europepmc.org/articles/PMC6779753

CS-15 Endothelial progenitor cells as a promising biomarker of systemic lupus erythematosus activity

Autor: Gonzalo Silveira, Sabrina Ranero, Adriana Carlomagno, Sofía Grille, Ãlvaro Danza, Martín Rebella

Publikováno v: Clinical Sciences.

Background Endothelial progenitor cells (EPC) and circulating endothelial cells (CEC) are cell populations mobilized from the bone marrow in response to endothelial damage. Its relationship with vascular risk damage and subclinical vascular damage in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ca0589fc2ebd2e65a740ef14815a6dd
https://doi.org/10.1136/lupus-2018-lsm.50